Sign In
Buy KYKOF
$14.20
+0 (+0%)
At Close: Jul 31, 2026
AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform
10:00am, Tuesday, 28'th Jan 2025
Longstanding relationship strengthens innovation, providing diverse stakeholders access to advanced AI-driven insights to accelerate therapeutic discovery and development Longstanding relationship str
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies
08:00pm, Monday, 09'th Dec 2024
BASEL, Switzerland--(BUSINESS WIRE)--Cimeio Therapeutics announced today that it has entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa Kirin) to develop a novel therapy for diseases w
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
05:52pm, Wednesday, 20'th Nov 2024
Kura Oncology said on Wednesday it will collaborate with Japan's Kyowa Kirin to develop and commercialize the blood cancer therapy ziftomenib.
Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company
02:40am, Thursday, 31'st Oct 2024
TOKYO--(BUSINESS WIRE)--Japan-based Global Specialty Pharmaceutical Company Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto.) (TOKYO:4151) today announced that Masashi Miyamoto, Ph.D. will
GALASHIELS & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced it will present interim find
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis
07:00am, Wednesday, 25'th Sep 2024
Rocatinlimab Met Co-Primary Endpoints of vIGA-ADTM 0/1 with a ≥ 2-Point Reduction from Baseline, EASI-75, and All Key Secondary Endpoints HORIZON is the First of Eight Phase 3 Trials in the ROCKET P
One oral presentation and nine posters will shed light on real-world experiences of people living with XLH and the impact of burosumab treatment TOKYO , Sept. 19, 2024 /PRNewswire/ -- Kyowa Kirin Co.,
Kyowa Kirin to end distribution of Fareston (toremefine) in the United States
11:05am, Friday, 23'rd Aug 2024
PRINCETON, N.J., Aug. 23, 2024 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd.
GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) and a Japan-based global specialty
Kyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC
07:30am, Monday, 10'th Jun 2024
Company's first manufacturing facility in North America to accelerate production of new biologic therapies to advance clinical pipeline Facility to draw upon local talent, area colleges and universiti
Kyowa Kirin Will Present Pre-Clinical Data at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
05:30pm, Wednesday, 08'th May 2024
PRINCETON, N.J. and TOKYO , May 8, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ® (istradefylline) and Other Parkinson's Disease Add-On Therapies
09:00am, Friday, 12'th Apr 2024
PRINCETON, N.J., April 12, 2024 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, will announ
PRINCETON, N.J. and TOKYO , April 2, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
Kyowa Kirin's gene therapy most expensive US drug with $4.3 mln price tag
08:49am, Wednesday, 20'th Mar 2024
Orchard Therapeutics, a unit of Japan's Kyowa Kirin , priced its newly approved gene therapy for a rare, life-threatening genetic disease on Wednesday at $4.25 million, making it the most expensive dr
Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
10:00am, Friday, 08'th Mar 2024
PRINCETON, N.J. and TOKYO , March 8, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
